New hope for COPD patients: targeted drug may cut dangerous Flare-Ups

This study tested whether mepolizumab, a drug that targets certain white blood cells (eosinophils), can reduce airway inflammation in people with COPD who have high levels of these cells. 18 participants received the drug or a placebo for 6 months. The goal was to see if the drug could lower eosinophil counts and prevent severe breathing attacks. While the drug may help control the disease, it is not a cure, and patients may still need ongoing treatment.